Cedars-Sinai Cancer
Cedars-Sinai Cancer appoints new vice chair of research
Indrin Chetty, PhD, has been appointed as the new vice chair of research at Cedars-Sinai Cancer.
Cedars-Sinai Cancer appoints director of melanoma research
Bin Zheng, PhD, has been appointed director of melanoma research in the department of biomedical sciences at Cedars-Sinai Cancer.
‘Heart-on-a-chip’ successfully predicts cardiotoxicity of cancer therapies
A miniature, three-dimensional heart model, called the “heart-on-a-chip,” successfully used reprogrammed stem cells to determine cardiotoxicity of cancer drugs on the human heart, according to a study published in Lab on a Chip.
‘Molecular twin’ platform could expand use of precision medicine in cancer care
Researchers used an artificial intelligence and precision medicine approach that identifies biomarkers that appear superior to standard tests for predicting pancreatic cancer survival, findings in Nature Cancer showed.
Nanomedicine specialist named chair in medical discovery at Cedars-Sinai
Lali Medina-Kauwe, PhD, has been named the inaugural Carol Moss Foundation chair in medical discovery at Cedars-Sinai.
Cedars-Sinai Cancer Center appoints gynecologic oncology fellowship program director
Margaret Liang, MD, MSPHM, has been appointed director of the gynecologic oncology fellowship program for Cedars-Sinai Cancer Center.
Y chromosome loss may be key to unlocking more effective bladder cancer treatment for men
A series of studies showed that loss of the Y chromosome helps cancer evade the body’s immune system response, resulting in more aggressive bladder cancer in men as they age.
Women with perinatal mood, anxiety disorders have specific altered proteins
Women who developed mood or anxiety disorders associated with pregnancy and childbirth had a specific and unique plasma protein signature regulating various neuronal signaling and proinflammatory pathways, researchers reported.
ACC expert consensus pathway highlights ‘revolutionary’ advances in HFpEF management
HF with preserved ejection fraction is a complex condition with multiple overlapping comorbidities that requires timely diagnosis and optimal guideline-based therapies, according to new guidance from the American College of Cardiology.
Phase 3 study of lung cancer regimen designed to be a model for increasing trial diversity
Researchers have begun enrolling patients in Pragmatica-Lung, an NCI-supported phase 3 study designed specifically to eliminate barriers to clinical trial accessibility and participation.